Head to Head Survey: Cellectis (NASDAQ:CLLS) vs. Cibus (NASDAQ:CBUS)

Cellectis (NASDAQ:CLLS) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings and Valuation

This table compares Cellectis and Cibus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59 million	1.54	-$67.59 million	($0.65)	-1.88
Cibus	$3.64 million	29.71	-$127.08 million	($1.65)	-0.86

Cellectis has higher revenue and earnings than Cibus. Cellectis is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.9% of Cellectis shares are held by institutional investors. Comparatively, 33.8% of Cibus shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 29.9% of Cibus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cellectis and Cibus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Cibus	-2,258.89%	-287.03%	-27.99%

Analyst Ratings

This is a summary of recent ratings and price targets for Cellectis and Cibus, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	2	2	2	1	2.29
Cibus	1	1	1	0	2.00

Cellectis presently has a consensus price target of $5.46, suggesting a potential upside of 345.71%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 536.04%. Given Cibus’ higher probable upside, analysts plainly believe Cibus is more favorable than Cellectis.

Risk & Volatility

Cellectis has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Comparatively, Cibus has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Summary

Cellectis beats Cibus on 11 of the 15 factors compared between the two stocks.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

About Cibus

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.